Teachers Retirement System of The State of Kentucky lessened its holdings in Alkermes Plc (NASDAQ:ALKS) by 1.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 77,701 shares of the company’s stock after selling 919 shares during the quarter. Teachers Retirement System of The State of Kentucky owned 0.05% of Alkermes worth $4,253,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also modified their holdings of the company. First Trust Advisors LP boosted its holdings in Alkermes by 18.6% in the fourth quarter. First Trust Advisors LP now owns 800,752 shares of the company’s stock worth $43,825,000 after acquiring an additional 125,309 shares in the last quarter. Bailard Inc. acquired a new stake in Alkermes in the fourth quarter worth about $274,000. Schwab Charles Investment Management Inc. raised its stake in shares of Alkermes by 5.0% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 493,515 shares of the company’s stock worth $27,011,000 after purchasing an additional 23,712 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Alkermes by 13.7% in the third quarter. Janus Henderson Group PLC now owns 2,650,006 shares of the company’s stock worth $134,726,000 after purchasing an additional 319,014 shares during the last quarter. Finally, AMP Capital Investors Ltd raised its stake in shares of Alkermes by 11.0% in the third quarter. AMP Capital Investors Ltd now owns 53,745 shares of the company’s stock worth $2,732,000 after purchasing an additional 5,306 shares during the last quarter.
Alkermes Plc (ALKS) opened at $61.25 on Friday. The company has a current ratio of 2.78, a quick ratio of 2.46 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $9,491.57, a P/E ratio of -59.47 and a beta of 1.87. Alkermes Plc has a 12-month low of $46.42 and a 12-month high of $71.22.
ALKS has been the subject of several research analyst reports. Credit Suisse Group set a $66.00 price objective on Alkermes and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Monday, February 5th. Morgan Stanley restated an “equal weight” rating and issued a $67.00 price objective (up from $60.00) on shares of Alkermes in a research note on Friday, February 23rd. Citigroup set a $62.00 price objective on Alkermes and gave the stock a “hold” rating in a research note on Thursday, February 15th. Finally, BidaskClub upgraded Alkermes from a “sell” rating to a “hold” rating in a research note on Wednesday, December 27th. Nine equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Alkermes presently has an average rating of “Hold” and a consensus price target of $64.58.
In related news, SVP Laurie Keating sold 6,249 shares of Alkermes stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $121.20, for a total transaction of $757,378.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Iain Michael Brown sold 10,652 shares of Alkermes stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $54.81, for a total value of $583,836.12. Following the transaction, the chief accounting officer now owns 16,943 shares of the company’s stock, valued at $928,645.83. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 125,433 shares of company stock valued at $7,942,327. 5.34% of the stock is owned by company insiders.
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.